A Novel Bromine-Induced Ring Expansion of the Spiroimine Moiety of the Shellfish Toxin Gymnodimine

Margaret A. Brimble; James E. Robinson; Jörn Merten; Veronica Beuzenberg; Michael Dragunow; Patrick Holland; Douglas Mountfort

doi:10.1055/s-2006-941605

LETTER

A Novel Bromine-Induced Ring Expansion of the Spiroimine Moiety of the Shellfish Toxin Gymnodimine

Margaret A. Brimble*^a, James E. Robinson^a, Jörn Merten^a, Veronica Beuzenberg^b, Michael Dragunow^c, Patrick Holland^c, Douglas Mountfort^c
^a Department of Chemistry, University of Auckland, 23 Symonds St., Auckland, New Zealand
Fax: +64(9)3737422; e-Mail: m.brimble@auckland.ac.nz;
^b Cawthron Institute, 98 Halifax St., Private Bag 2, Nelson, New Zealand
^c Department of Pharmacology, University of Auckland, Auckland, New Zealand

Abstract

All articles of this category

Abstract

Treatment of the shellfish toxin gymnodimine with one equivalent of molecular bromine at -78 °C resulted in stereoselective formation of a novel ring-expansion product. Participation of the spiromine unit in this novel bromine-induced ring expansion reaction provides insight into how the reactivity of spiroimine moiety may contribute to the toxicity of this marine biotoxin when activated by the presence of an appropriate environmental electrophile.

Key words

gymnodimine - shellfish toxin - ring expansion

Full Text

References

References and Notes

<A NAME="RD03706ST-1">1</A> Seki T. Satake M. Mackenzie L. Kaspar HF. Yasumoto T. Tetrahedron Lett. 1995, 39: 7093

<A NAME="RD03706ST-2">2</A> Stewart M. Blunt JW. Munro MHG. Robinson WT. Hannah DJ. Tetrahedron Lett. 1997, 38: 4889

<A NAME="RD03706ST-3">3</A> Hu TM. Burton IW. Cembella AD. Curtis JM. Quilliam MA. Walter JA. Wright JLC. J. Nat. Prod. 2001, 64: 308

<A NAME="RD03706ST-4">4</A> Chou T. Haino T. Kuramoto M. Uemura D. Tetrahedron Lett. 1996, 37: 4027

<A NAME="RD03706ST-5">5</A> Takada N. Umemura N. Suenaga K. Uemura D. Tetrahedron Lett. 2001, 42: 3495

<A NAME="RD03706ST-6">6</A> Munday R. Towers NR. MacKenzie L. Beuzenberg V. Holland PT. Miles CO. Toxicon 2004, 44: 173

<A NAME="RD03706ST-7">7</A> Gill S. Murphy M. Clausen J. Richards D. Quilliam MA. MacKinnon S. LeBlanc P. Mueller R. Pulido O. NeuroToxicology 2003, 24: 593

<A NAME="RD03706ST-8">8</A> Dragunow M. Trozss M. Brimble MA. Cameron R. Beuzenberg V. Holland P. Mountfort D. Environ. Toxicol. Pharmacol. 2005, 20: 305

<A NAME="RD03706ST-9">9</A> Tehrani KA. Van Syngel K. Boelens M. Contreras J. De Kimpe N. Knight DW. Tetrahedron Lett. 2000, 41: 2507

<A NAME="RD03706ST-10">10</A> De Kimpe N. Boelens M. Piqueur J. Baele J. Tetrahedron 1994, 35: 1925

<A NAME="RD03706ST-11">11</A> Miyano S. Mibu N. Irie M. Sumoto K. Heterocycles 1986, 24: 2121

<A NAME="RD03706ST-12">12</A> Sumoto K. Mibu N. Irie M. Abe N. Miyano S. Chem. Pharm. Bull. 1990, 38: 577

Isolation and Purification of Gymnodimine ( 1).
Gymnodimine was isolated from a laboratory culture of Karenia selliformis (syn Gymnodinium selliforme CAW D79) at the Cawthron Institute (Nelson, New Zealand). The extraction and purification procedure was based on the reported method, see ref. 14. Prior to passage through an HP-20 resin the culture was acidified with 50% HCl to pH 4.5 and filtered (Toyo GC 90, 124 mm). The toxin was eluted off the HP-20 resin with MeOH, concentrated to low volume and clean-up achieved by solvent partitioning. The purity of the isolated toxin was checked by 600 MHz ¹H NMR spectroscopy and LCMS. Two impurities, unknown isomers of gymnodimine, were detected at ca. 4%. The crude extract was further purified by flash column chromatography using CH₂Cl₂-MeOH-Et₃N (10:0.2:0.2) as eluent to obtain a white solid.

<A NAME="RD03706ST-14">14</A> Miles CO. Wilkins AL. Stirling DJ. MacKenzie AL. J. Agric. Food Chem. 2000, 48: 1373

Synthesis of Ring-Expansion Product 2. To a solution of gymnodimine (1, 10 mg, 19.7 µmol) in CH₂Cl₂ (2 mL) was added dropwise a solution of bromine in CH₂Cl₂ (0.5 M, 44 µL, 22 µmol) at -78 °C and stirring was continued for 5 min. The colourless mixture was warmed to r.t. and directly subjected to flash chromatography (CH₂Cl₂-MeOH, 85:15). The ring-expansion product 2 (9.7 mg, 81%) was obtained as a colourless wax. R _f = 0.44 (CH₂Cl₂-MeOH, 85:15); [α]_D ²⁰ 11.3 (CHCl₃, c 1.24 g/100 mL). ¹H NMR (600 MHz, CDCl₃): δ = 1.04 (m, 1 H, 17-H_a), 1.21 (d, J = 7.3 Hz, 3 H, 14-H₃), 1.72 (s, 1 H, 21-H₃), 1.75 (s, 3 H, 34-H₃), 1.76-2.20 (m, 12 H, 4-H₂, 5-H₂, 15-H₂, 17-H_b, 18-H_2, 26-H₂, 27-H_a), 1.93 (s, 3 H, 32-H₃), 2.23 (s, 3 H, 11-H₃), 2.51-2.60 (m, 2 H, 13-H, 27-H_b), 2.71 (m, 2 H, 8-H₂), 2.87 (m, 1 H, 7-H_a), 3.32 (d, J = 10.4 Hz, 23-H), 3.46 (m, 1 H, 7-H_b), 3.96-4.03 (m, 2 H, 6-H_a, 16-H), 4.19 (m, 2 H, 6-H_b, 19-H), 4.40 (d, J = 6.2 Hz, 1 H, 12-H), 4.93 (dd, J = 8.9, 8.9 Hz, 1 H, 9-H), 5.48 (d, J = 10.6 Hz, 1 H, 22-H), 5.81 (s, 1 H, 28-H), 6.94 (s, 1 H, 33-H). ¹³C NMR (150 MHz, CDCl₃): δ = 10.6 (q, C-32), 11.5 (q, C-21), 17.2 (q, C-34), 18.5 (t, C-26), 20.4 (t, C-4), 21.1 (q, C-14), 22.1 (t, C-18), 25.5 (q, C-11), 26.9 (t, C-8), 30.4 (t, C-27), 31.8 (t, C-5), 32.8 (t, C-7), 34.3 (t, C-17), 35.9 (d, C-13), 40.2 (t, C-15), 45.9 (s, C-3), 48.8 (d, C-23), 51.1 (t, C-6), 66.2 (s, C-10), 77.8 (d, C-16), 79.1 (d, C-19), 79.8 (2 × d, C-9, C-28), 95.6 (d, C-12), 123.8 (d, C-22), 126.4 (s, C-24), 130.7 (s, C-31), 131.7 (s, C-25), 144.9 (s, C-20), 146.7 (d, C-33), 174.3 (s, C-30), 198.5 (s, C-2). IR (film): ν = 3019, 2400, 1755, 1220, 770 cm^-1. HRMS: m/z calcd for C₃₂H₄₅ ⁷⁹BrNO₄ [MH⁺ - H₂O]: 586.2532; found: 586.2527.

<A NAME="RD03706ST-16">16</A> For an example of electrophilic activation of a prodrug, see: Dao V.-T. Dowd MK. Gaspard C. Martin M.-T. Hémez J. Laprévote O. Mayer M. Michelot RJ. Bioorg. Med. Chem. 2003, 11: 2001